Aker BioMarine reported fourth-quarter 2025 revenues of $55.2 million, up 6% year on year, with adjusted EBITDA of $10.6 million, an increase of 66% compared with the same period last year.
The company’s Human Health Ingredients segment generated revenues of $32.7 million, up 28% year on year, supported by strong volume growth and an improved price mix. Adjusted EBITDA for the segment increased 59% to $14.1 million.
Consumer Health Products recorded revenues of $26.9 million, down 8% year on year, reflecting lower-than-expected demand growth and continued pressure in drugstore channels. The company said EBITDA in the segment improved on better gross margins and continued cost control.
The Emerging Business segment reported revenues of $2.0 million, broadly stable compared with previous quarters, and an adjusted EBITDA loss of $0.5 million.
Aker BioMarine said a large new customer for krill oil was fully onboarded during the quarter, delivering strong initial performance. The company also confirmed that, following recent interest in its Human Health Ingredients business unit, it has engaged advisers to explore strategic alternatives and work towards a potential transaction in 2026.
“We delivered another solid quarter with continued improvement in profitability, driven primarily by strong performance in Human Health Ingredients. It was also particularly exciting with launch of a new krill oil brand in Costco during the quarter, which has delivered great performance in the initial phase,” said Matts Johansen, chief executive of Aker BioMarine.
For the first quarter of 2026, the company expects krill oil revenues to increase by 15% to 30% year on year, supported by good underlying demand across multiple markets. In Consumer Health Products, revenues are expected to follow broader market growth over time. The Emerging Business segment remains on track toward cash break-even.
At group level, Aker BioMarine said it has established a leaner cost base and is executing initiatives to further improve financial and operational efficiency, while assessing potential impacts from increased macroeconomic uncertainty and new tariffs.
The company has engaged Jefferies and Houlihan Lokey as financial advisers in relation to the review of its Human Health Ingredients business.